Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Adobe

Automatic Data Processing

American Electric Power Company

Applied Materials

Advanced Micro Devices

Broadcom

Cisco Systems

Dominion Energy

Duke Energy

Eversource Energy

General Motors

Alphabet

Intuit

Oracle

A summer swoon that has been chipping away at stocks since early July was egged on Tuesday with news that Americans have hardly curbed their spending.

Here are the stocks to buy and the ones to sell if interest rates stay high, says Jefferies

Novo Nordisk

Pfizer

Risk-on sentiment and end of pandemic boom have weighed on healthcare. Health insurers and medical device firms have held up better.

Outlook For Healthcare Sector As Obesity Drugs Gain Popularity

Emerson Electric

PepsiCo

The bulk of the Q2 season is in the rearview mirror, but the quarterly results from these 3 Dividend Aristocrats shouldn't be ignored.

3 Dividend Aristocrats Positively Surprising Investors

American Tower

Colgate-Palmolive

Medtronic

Schlumberger

Telefonica SA

Texas Instruments

There's a reasonable argument to be made that investors should load up on blue-chip stocks regularly. After all, large and well-established firms with long track records of success are likely to continue to be successful.

7 Blue-Chip Stocks Smart Investors Should Be Loading Up on Now

Home Depot

Johnson & Johnson

Kroger

Philip Morris

Sempra Energy

While optimism in the broader market remains robust – particularly for hyped-up sectors like technology – investors may still want to consider the relative safety of dividend stocks to buy. Notably, in the trailing month, the benchmark S&P 500 index went absolutely nowhere.

7 Dividend Stocks to Buy as Investor Sentiment Falters

Dividend yields, dividend growth, and valuation were among the key factors in evaluating the Dividend Kings. Business models and overall growth prospects were considered as well.

My Top Dividend King to Buy and Hold for the Next 10 Years, and It Isn't Even Close

Equinix

T-Mobile US

Walmart

In the ever-fluctuating stock market landscape, navigating bear markets can be a nerve-wracking experience for even the most seasoned investors. When stock prices plunge and economic clouds gather, it's natural to question whether investing during such turbulent times is wise.

5 Best Stocks to Buy in a Bear Market

Seagen

There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

GlaxoSmithKline

Moderna

With pharmaceutical companies, it's all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions.

3 Pharma Stocks to Sell in August Before They Crash and Burn

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Federal Realty Investment Trust

NextEra Energy

Realty Income Corp

Sysco

Target

T. Rowe Price Group

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. " - Kiplinger.com/Investing. 66 Aristocrats, screened as of August 9, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net gains ranged 15.54%-31.28% topped by TGT and NEE. By yield, WBA topped-all Aristocrats. Top-ten Yields from ESS, ABBV, FRT, BEN, TROW, IBM, AMCR, O, MMM, & WBA, averaged 4.78%.

3 Dividend Aristocrat Buys For August And 6 To Watch

DoorDash

Coca-Cola

AbbVie, Coca-Cola, and DoorDash are coming off better-than-expected quarters. These three companies all all feeling more optimistic about the rest of 2023.

3 Stocks That Recently Raised Their Guidance for the Year

Accenture Plc

ASML Hld

Best Buy

Blackrock Inc

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 2.44% in July, underperforming the S&P 500 by 0.77%. Year-to-date, the portfolio is up 14.72%. Since inception, the portfolio is generating 2.75% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Performance Since Launch

News for AbbVie Stock (ABBV)